CD38 and Miyoshi myopathy: A new humanized IgG1 anti-CD38 MoAb, mezagitamab (TAK 079), also showed robust anti-MM activity in RRMM samples and immunomodulatory effects, including activation of NK and T cells, as well as suppression of immune inhibitory cells [150].